Financial Data and Key Metrics Changes - The company achieved a 35% year-over-year reduction in pro forma operating expenses, reflecting improved efficiency and focus on portfolio optimization [14][49]. - Cash operating expenses for 2026 are expected to be under $390 million, with a cash balance of $754 million at the end of 2025, extending the cash runway to early 2028 [49][52]. Business Line Data and Key Metrics Changes - The company reported significant progress in its clinical development, including a positive proof of concept for FAP, which has the potential to be a first-in-class treatment [8][18]. - The partnership with Sanofi has resulted in five milestones achieved, contributing to over $500 million in total cash inflows from partnerships [35][36]. Market Data and Key Metrics Changes - The company is leveraging both public and proprietary data to enhance its AI-driven platform, which is critical for generating impactful medicines [5][41]. - The integration of AI across the full life cycle of R&D is seen as a key differentiator in the competitive landscape of the biotechnology industry [2][10]. Company Strategy and Development Direction - The company is focused on three strategic pillars: tangible proof points in clinical and partner programs, surgical investment in its platform, and disciplined execution to maximize impact [10][11]. - The emphasis is on unlocking value through AI-driven insights, improving decision-making across R&D, and ensuring that the platform can deliver better targets and molecules [3][7]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the broader momentum in the biotechnology sector, highlighting the importance of translating AI capabilities into real-world applications [2][4]. - The company is on track for initial engagement with the FDA regarding REC-4881 and anticipates additional clinical data in the coming years [53][57]. Other Important Information - The company has built over 50 petabytes of high-quality multimodal data, which is essential for developing state-of-the-art foundation models in biology and chemistry [40][41]. - The integration of a newly built clinical development AI platform is expected to improve enrollment rates and operational efficiency in clinical trials [46][47]. Q&A Session Summary Question: What is the potential registrational pathway for REC-4881? - The company is on track for initial engagement with the FDA in the first half of 2026 to discuss the registrational study design and patient population [56][57]. Question: Are there any one-off cost-cutting measures that helped in Q4? - The CFO clarified that the focus is on efficiency rather than one-off measures, with expectations to continue finding ways to do more with less [58][60]. Question: What is the rationale behind the divestment from NVIDIA? - The company emphasized that the technical collaboration with NVIDIA continues, while the divestment reflects NVIDIA's shift in investment strategy [62][63].